重组人LH补充对超重/肥胖女性累积活产率的影响:一项回顾性队列研究
该回顾性队列研究纳入2013至2021年南京医科大学第一附属医院791个取卵周期,比较重组人FSH联合重组人LH与单用重组人FSH在超重/肥胖IVF女性中的效果。倾向性评分1:1匹配后每组130个周期,结果显示联合组累积活产率65.38% vs 单用组72.31%,差异无统计学意义(P=0.228)。结论认为补充rhLH未显著改善累积活产率或妊娠结局。
要点
- 匹配后联合组累积活产率65.38%(85/130) vs 单用组72.31%(94/130),P=0.228,无显著差异。
- 联合组促性腺激素起始剂量和总剂量均显著高于单用组(P<0.001)。
- 联合组扳机日雌二醇浓度和获卵数均显著低于单用组(P=0.007和P=0.029)。
核心结论
- 在超重/肥胖接受IVF的女性中,与单用重组人FSH相比,联合补充重组人LH未显著改善累积活产率或妊娠结局。
研究设计与样本
- 回顾性队列研究,在中国南京医科大学第一附属医院临床生殖医学中心开展,分析2013至2021年IVF临床数据。
- 共纳入791个取卵周期,分为重组人FSH联合重组人LH组和单用重组人FSH组,采用倾向性评分1:1匹配后每组130个周期进入最终分析。
- 主要结局为累积活产率(CLBR)。
主要发现
- 匹配后两组基线特征可比;联合组促性腺激素起始剂量200(IQR 175-225)IU vs 单用组175(IQR 150-200)IU,P<0.001;总剂量1800(IQR 1581.25-2200)IU vs 1600(IQR 1350-1925)IU,P<0.001。
- 联合组扳机日雌二醇浓度12,332.95(IQR 7547.1-18,036.64)pmol/l vs 单用组15,881.00(IQR 9616.88-21,487)pmol/l,P=0.007;获卵数10(IQR 7-13.75) vs 11(IQR 9-14),P=0.029。
- 首次胚胎移植后生化妊娠率71.65% vs 67.20%(P=0.443)、临床妊娠率61.42% vs 60.80%(P=0.920)、流产率20.51% vs 10.53%(P=0.088)、活产率48.82% vs 54.40%(P=0.375),均无显著组间差异。
- 累积活产率85/130(65.38%) vs 94/130(72.31%),P=0.228;调整促性腺激素起始剂量、总剂量、扳机日雌二醇浓度及获卵数等潜在混杂因素后逻辑回归结果一致。
- 产科-围产期并发症无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Does recombinant human LH (rhLH) supplementation improve the cumulative live birth rate (CLBR) in overweight/obese women undergoing IVF? DESIGN: This retrospective cohort study was conducted at the Centre for Clinical Reproductive Medicine of the First Affiliated Hospital of Nanjing Medical University, China. Clinical data of patients who underwent IVF from 2013 to 2021 were analysed. In total, 791 oocyte retrieval cycles were included and categorized into recombinant human FSH (rhFSH)/rhLH and rhFSH alone groups. Propensity score matching (PSM) for potential confounders was performed in a 1:1 ratio. After matching, 130 cycles from each group were included in the final analyses. The primary outcome was CLBR. RESULTS: Baseline characteristics of the two groups were comparable after PSM. The gonadotrophin starting dose [200 (IQR 175-225) IU versus 175 (IQR 150-200) IU, P < 0.001] and the total gonadotrophin dose [1800 (IQR 1581.25-2200) IU versus 1600 (IQR 1350-1925) IU, P < 0.001] were significantly higher in the rhFSH/rhLH group compared with the rhFSH alone group. Patients in the rhFSH/rhLH group had a lower oestradiol concentration on trigger day [12,332.95 (IQR 7547.1-18,036.64) pmol/l versus 15,881.00 (IQR 9616.88-21,487) pmol/l, P = 0.007] and fewer oocytes retrieved [10 (IQR 7-13.75) versus 11 (IQR 9-14), P = 0.029] compared with the rhFSH alone group. There were no significant intergroup differences in the rates of biochemical pregnancy (71.65% versus 67.20%, P = 0.443), clinical pregnancy (61.42% versus 60.80%, P = 0.920), miscarriage (20.51% versus 10.53%, P = 0.088) and live birth (48.82% versus 54.40%, P = 0.375) after first embryo transfer. CLBR was also similar [85/130 (65.38%) versus 94/130 (72.31%), P = 0.228]. Results remained consistent on logistic regression after adjusting for potential confounders such as gonadotrophin starting dose, total gonadotrophin dose, oestradiol concentration on trigger day, and oocyte number retrieved. There were no significant differences in obstetric-perinatal complications. CONCLUSION: In overweight/obese women undergoing IVF, rhFSH supplementation with rhLH did not significantly improve CLBR or pregnancy outcomes compared with rhFSH alone.
引用
- Zhou X, Ren L, Ma X, et al. Recombinant LH supplementation and cumulative live birth rate in overweight/obese women: a retrospective cohort study. Reprod Biomed Online. 2025. PMID: 41138397. doi:10.1016/j.rbmo.2025.105076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。